This is a multicentre, open label, randomized, pilot study to evalute safety and efficacy of Human Platelet Lysate (HPL) in subjects with Periorbital Hyperpigmentation. The study is being conducted at 2 centers in India.The primary endpoints are Physicians and Patient Self assessment score. The secondary endpoints are improvement in photographic assessment form randomization to end of study.

Inclusion Criteria:

• Subjects (male and female), aged 18 to 55 years (both inclusive) with Periorbital Hyperpigmentation.
• Subject willing to refrain from any other treatment of Periorbital Hyperpigmentation during entire study duration.
• Subjects who are willing to give informed consent and adhere to the study protocol.

Exclusion Criteria:

• Subjects aged less than 18 and more than 55 years
• Subjects with history of connective tissue disease.
• Subjects with metabolic or hematopoietic disorders
• Subjects unwilling to or unable to comply with the study protocol.
• Subjects taking concomitant therapy that might interfere with the study results in the investigator's opinion or participating in another trial in the past 30 days.